Daniel S. Berger, M.D.
Daniel S. Berger, M.D., is Medical Director of NorthStar Healthcare in Chicago and is Clinical Assistant Professor of Medicine at the University of Illinois at Chicago; he is also a Fellow of the American College of Nutrition.
Dr. Berger earned his medical degree at the Finch University of Health Sciences/Chicago Medical School in North Chicago. He completed an internship at Lutheran General Hospital in Park Ridge, Ill., and postgraduate training at Saint Joseph Hospital in Chicago.
Dr. Berger has been a full-time practitioner specializing in HIV and AIDS and is the Founder and Medical Director of the largest private HIV treatment and research center in the greater Chicago area, NorthStar Healthcare. Dr. Berger is well-known nationally and internationally among HIV specialists, researchers and individuals engaged in HIV drug development within the pharmaceutical industry. He has authored and co-authored more than 50 articles and abstracts in juried national and international conferences and peer-reviewed medical journals and an additional 50 articles in lay and community publications. Dr. Berger has written on such topics as AIDS wasting, lipodystrophy, antiretroviral therapies, immune response modifiers and HIV drug resistance. He has also authored a book chapter entitled, "Enteral & Parenteral Support in Nutritional Aspects of HIV Infection" (Oxford University Press, 1999). As principle investigator, he has conducted more than 100 clinical research trials for HIV-related treatments and recently completed the phase I study investigating the safety and effect of a novel candidate HIV-1 integrase inhibitor (GS 9137); he co-authored the late-breaker presentation at the Conference on Retroviruses and Opportunistic Infections in February 2006. Dr. Berger is one of the lead U.S. investigators and has extensive clinical experience and involvement in multiple protocols with the recently approved protease inhibitor TMC114 (darunavir, Prezista). His involvement in studies of multiple key candidate agents for the treatment of HIV infection also include non-nucleoside reverse transcriptase inhibitors TMC125 (etravirine) and TMC278, entry inhibitors aplaviroc (GW873140) and maraviroc (UK-427857), protease inhibitor brecanavir (GW640385) and two novel integrase inhibitor agents, GS 9137 and MK-0518. Dr. Berger has served as a consultant on strategic planning committees for clinical trial design and development of Tibotec Pharmaceuticals compounds TMC114, TMC125 and TMC278. Dr. Berger also served on the national Tibotec External Clinical Review Panel to provide individual basis recommendations for patients to gain access for TMC114, when ineligible for clinical trial participation.
Dr. Berger has given numerous lectures to the public, medical community, and physicians both in Chicago and nationally. He was editor and founder of AIDS InfoSource, a national AIDS newsletter quarterly in 1994-2000, and is a monthly columnist and medical consultant for Positively Aware, a nationally distributed AIDS magazine. His column, The Buzz, is a well-known fixture of Positively Aware and is often featured on TheBody.com Web site. Dr. Berger also serves as an editorial board member for Contagion: Reports, Cases, and Commentaries in HIV and Infectious Disease Research. Additionally, Dr. Berger has recently used his medical expertise in contributing to, and authoring the Foreword for the recently published book, The First Year -- HIV, An Essential Guide for the Newly Diagnosed (2003, Marlowe & company), a valuable resource for patients who are coming to terms with their HIV infection. He served on the Board of Directors for Test Positive Aware Network, Chicago's oldest AIDS service organization and currently serves on the Board of Directors for the AIDS Foundation of Chicago. Dr. Berger is also a member of the HIV Medical Issues Committee for the Illinois AIDS Drug Assistance Program; his work has resulted in important policy changes in the Illinois ADAP formulary.
Dr. Berger has received an award for Distinguished Research in HIV Medicine from Serono Labs and is being honored this year by Test Positive Aware Network with the Charles E. Clifton Leadership Award for the many years of service to the Chicago HIV/AIDS community.
Daniel S. Berger, M.D., is a consultant for Gilead Sciences, GlaxoSmithKline, and Tibotec Therapeutics. Dr. Berger is a stockholder of Gilead Sciences and serves on the Speakers' Bureau for Gilead Sciences, GlaxoSmithKline, and Tibotec Therapeutics. Dr. Berger has also indicated that he plans to discuss investigational and/or unlabeled uses of products.